CATALYSTYahoo Finance • 14h ago
Trevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book ValueYahoo Finance report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
Why TRVI Stock slipped -1.81% Today — RQD Quant Desk Flash
$13.56 -1.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $13.49
Trevi Therapeutics Inc. (TRVI) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.97B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TRVI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TRVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Trevi Therapeutics Inc. (NASDAQ: TRVI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $13.56 (-1.81% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TRVI ranks #839 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TRVI compare to XERS and ZYME in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRVI carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -23.7%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.96B) and ZYME (Zymeworks Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, TRVI leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TRVI?
▼
Per TRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001563880), Trevi Therapeutics Inc. generated $0 in revenue, -$42.8M in net income, and -$42.1M in free cash flow against $193.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $13.49 (-0.52%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRVI)Realized 20D OHLCV Swing Band: ±11%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY TRVI SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)
20D Institutional Volume Accumulation (±11% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$12.93-8% Next Q
22
Q2 (-2Q)Grade E$11.90+5.1% Next Q
25
Q3 (-1Q)Grade E$12.51+8.4% Next Q
27
CurrentGrade E$13.56-9.6% Hist 90D α
30
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TRVI Turnaround Squeeze
While TRVI currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.61) and Max Pain ($14.24) forces dealer call-delta covering toward $21.23.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRVI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TRVI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TRVI Stock slipped -1.81% Today — RQD Quant Desk Flash
Trevi Therapeutics Inc. (TRVI) slipped -1.81% to $13.56, trading at 36% of its 52-week range ($9.82 – $20.22). Stretched risk/reward at current multiples (-24% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 36% of its 52-week range ($9.82 – $20.22) with RSI-14 at 53.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11% around $13.56 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TRVI Headlines & Catalysts
MARKET WIREStockInvest.us • 17h ago
Trevi Therapeutics Stock Price Forecast. Should You Buy TRVI?StockInvest.us report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 20h ago
BMO reiterates Trevi Therapeutics stock rating after rival study failsInvesting.com report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 23h ago
Trevi Therapeutics Q2 2026 Earnings Call TranscriptBenzinga report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Do Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions?Yahoo Finance report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Patients reported early, sustained improvement in a chronic-cough trialStock Titan report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Trevi Therapeutics (TRVI) Following GSK Exit Is Its Chronic Cough Valuation Back In FocusSimply Wall St report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 1d ago
Trevi Therapeutics, Inc. (TRVI) Seasonal returns chartYahoo Finance UK report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 6d ago
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare ConferenceFireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ETNEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company devel
MARKET WIREYahoo • 20d ago
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingProfessor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)NEW HAVEN, Co
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRVI)
- ✓Walkthrough of TRVI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TRVI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.70%▼ DESCENDING CHANNEL
2026-11-02O $13.52H $13.81L $13.52C $13.56VOL 1.35M
RES: $17.87SUP: $10.95SMA50: $14.61SMA200: $14.36
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TRVI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TRVI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TRVI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TRVI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRVI)
Health Care Rank #839 of 1016
⚔️ XERS vs TRVI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TRVI vs. XERS, ZYME, GENB, BRVE)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Trevi Therapeutics Inc. (TRVI) ranks #839 by composite RQD confidence (30/100, grade E) and #266 by equity capitalization ($1.97B). Within this direct 5-issuer industry benchmark cohort, TRVI leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with TRVI at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TRVI
ACTIVE
Trevi Therapeutics Inc. | E | 30/100 | — | — | -23.7% | -1.81% | $1.97B | Benchmark Subject |
| XERS Xeris Biopharma Holdings Inc. | C | 64/100 | — | — | 16.0% | -0.37% | $1.96B | /xers-vs-trvi → |
| ZYME Zymeworks Inc. | D | 49/100 | — | — | -32.2% | -0.35% | $2.02B | /zyme-vs-trvi → |
| GENB Generate Biomedicines Inc. | D+ | 57/100 | — | — | — | -8.31% | $2.02B | /genb-vs-trvi → |
| BRVE Braveheart Bio Inc. | D | 46/100 | — | — | — | +1.51% | $1.91B | /brve-vs-trvi → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001563880In its most recent audited fiscal period (FY2025, filed 2025-12-31), Trevi Therapeutics Inc. (TRVI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$42.8M, operating cash flow of -$42.1M, and free cash flow of -$42.1M (-10.0% YoY). On the balance sheet, TRVI closed FY2025 with $193.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$42.8M | -$42.1M | -$42.1M | $193.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$47.9M | -$38.3M | -$38.3M | $110.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$29.1M | -$31.7M | -$31.7M | — | — |
3. TRVI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TRVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Trevi Therapeutics Inc. (NASDAQ: TRVI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $13.56 (-1.81% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TRVI ranks #839 in composite RQD confidence.
How does TRVI compare to XERS and ZYME in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRVI carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -23.7%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.96B) and ZYME (Zymeworks Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, TRVI leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TRVI?
Per TRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001563880), Trevi Therapeutics Inc. generated $0 in revenue, -$42.8M in net income, and -$42.1M in free cash flow against $193.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TRVI trading relative to its 50-day, 200-day, and 52-week technical levels?
TRVI last traded at $13.56 (-1.81% on volume of 1,732,030 shares), positioning the stock -7.19% below its 50-day simple moving average ($14.61) and -5.57% below its 200-day simple moving average ($14.36). Across its 52-week range of $9.82 to $20.22, TRVI sits at the 36.0% percentile with a 14-day RSI of 53.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($12.07 to $15.05).
TRVI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TRVI stock moving today?
Why TRVI Stock slipped -1.81% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-24% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
TRVI — Trevi Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:27:10Z
Roarable Rating Brief: What This Means to a Prospective Investor
The per the Roarable RQD rating, TRVI carries an RQD Score of 30 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 4 / 20. Per the RQD rating, ROIC is -23.7% and FCF yield is -2.14%. For a prospective investor, this means the business is consuming capital rather than generating it, so the equity case depends on future outcomes not yet visible in reported cash flows.
- Whale 13F Flow: 7 / 20. The RQD rating describes institutional accumulation and options positioning as a modest contributor. The holder-level detail needed to verify this is not available in source data, so the pillar cannot be traced to specific filers.
- Insider Conviction: 3 / 20. The RQD rating scores SEC Form 4 and Congressional PTR cluster flow weakly. An investor should read this as limited insider signaling in either direction, with the underlying transactions not available in source data.
- Macro Regime Fit: 6 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity. This implies TRVI tracks broad market moves one-for-one, offering no defensive cushion and no independent diversification benefit.
- Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. The Z-score sits in a middle zone, and the weak Piotroski reading signals poor fundamental health momentum.
Taken together, the score reflects a company with heavy cash burn, no revenue, and a fragile fundamental profile. Valuation tradeoffs are central: with no positive earnings, a multiple-based valuation cannot be anchored to reported profits, so the price rests on expectations not captured in the financial data. Upside would require a clear reversal in cash generation or a catalyst that re-rates the equity; the downside risk is compounded by the forensic weakness. The rating is presented as an analytical framework, not as personalized financial advice.
Business
Trevi Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, it has a market capitalization of $2.0B. The source data does not describe its specific products, target customers, or revenue model. Reported revenue is $0.0M across the available periods, so the company's commercial monetization is not evident in the reported financials.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-49.3M | $-42.8M | N/A | $-42.1M | $18.9M | N/A |
| FY 2024 | $0.0M | $-51.5M | $-47.9M | N/A | $-38.3M | $34.1M | N/A |
| FY 2023 | $0.0M | $-33.9M | $-29.1M | N/A | $-31.7M | N/A | N/A |
Per the SEC financials, the company reported operating and net losses in every available period, with gross, operating, and net margins all at 0%. Per the Roarable RQD rating, ROIC is -23.7% and the Altman Z-Score is 2.5 with a Piotroski F-Score of 3/9. Cash declined from $34.1M in FY 2024 to $18.9M in FY 2025, and the Debt/Equity ratio is 0.5 per the RQD rating, indicating a balance sheet under continuing cash pressure.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the most recent headlines include an analyst-style valuation piece from Yahoo Finance, a StockInvest.us price forecast, and a Benzinga Q2 2026 earnings call transcript. A Investing.com report notes that BMO reiterated its rating after a rival study failed. A Stock Titan report describes patients reporting early, sustained improvement in a chronic-cough trial. A Yahoo Finance piece links TRVI's CORAL data and GSK's exit to its chronic-cough ambitions. The news feed carries green and yellow signal flags, with the catalyst-tagged item being the valuation-related article. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no graph-derived catalysts are available. Risk watch items include the cash decline and the absence of revenue visible in the reported financials.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Upstream and downstream dependencies are therefore not available in source data. Sector correlations beyond the beta of 1.0 are not available in source data. The main ripple a prospective investor should watch is the company's dependence on its clinical-stage pipeline, as indicated by the news wire's trial and partnership references, since a shift in those programs would transmit directly to cash burn and valuation.
Open Questions
- What specific products or clinical programs drive the company's valuation, and what is their stage and timeline?
- What is the remaining cash runway at the current burn rate, given cash of $18.9M against FY 2025 free cash flow of $-42.1M?
- What are the terms and economic structure of the GSK arrangement referenced in the news feed?
- Who are the institutional and insider holders, and what are their recent position changes?
- What analyst consensus, rating, or price targets exist for TRVI?
TRVI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Trevi Therapeutics Inc. (TRVI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 14h ago
Trevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book Value Yahoo Finance report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 17h ago
Trevi Therapeutics Stock Price Forecast. Should You Buy TRVI? StockInvest.us report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 20h ago
BMO reiterates Trevi Therapeutics stock rating after rival study fails Investing.com report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 23h ago
Trevi Therapeutics Q2 2026 Earnings Call Transcript Benzinga report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Do Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions? Yahoo Finance report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Patients reported early, sustained improvement in a chronic-cough trial Stock Titan report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Trevi Therapeutics (TRVI) Following GSK Exit Is Its Chronic Cough Valuation Back In Focus Simply Wall St report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
Trevi Therapeutics, Inc. (TRVI) Seasonal returns chart Yahoo Finance UK report covering Trevi Therapeutics Inc. (TRVI) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
TRVI Bull vs. Bear Conversation Board — What's Your Call at $13.56?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TRVI 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $12.15 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is TRVI (E • RQD 30/100) a Buy at $13.81?
Welcome to the TRVI (Trevi Therapeutics Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $11.05 (-20.0%)
Spot @ $13.81 Pump the brakes on TRVI — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on TRVI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Trevi Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $16.30 (+18.0%)
Spot @ $13.81 TRVI cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on TRVI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $13.81 (52-wk range $9.82 - $20.22), any beat on forward guidance forces shorts and underweight funds to chase.